GlassScriptPhysician profile
Arabinda Chatterjee
NPI 1043278674
$14,722.55
in general payments reported to CMS, 2019-2025
42 companies · $2,426 in 2025
The $2,426 reported for 2025 was more than what 97% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,790 · 2020: $1,422 · 2021: $2,170 · 2022: $1,557 · 2023: $1,815 · 2024: $2,543 · 2025: $2,426.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,772 · Education: $11.29.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,772.41 |
| Education | $11.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,317.18 | 2019-2025 | Airsupra, Breztri, Tezspire |
| Abbvie INC. | $1,452.91 | 2019-2025 | Ubrelvy |
| Glaxosmithkline, LLC. | $1,345.55 | 2019-2025 | Trelegy Ellipta, Arexvy |
| Novo Nordisk INC | $1,065.01 | 2019-2025 | Ozempic, Wegovy, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $797.14 | 2019-2025 | Jardiance, Synjardy |
| Phathom Pharmaceuticals, INC. | $711.05 | 2024-2025 | Voquezna |
| Lilly USA, LLC | $631.24 | 2019-2025 | Jardiance, Mounjaro, Emgality |
| Bayer Healthcare Pharmaceuticals INC. | $620.57 | 2021-2025 | |
| Amgen INC. | $574.04 | 2019-2023 | Repatha |
| Teva Pharmaceuticals USA, INC. | $540.53 | 2020-2023 | Austedo Xr |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $408.66 | 2019-2022 | |
| Allergan, INC. | $395.52 | 2019-2020 | |
| Actelion Pharmaceuticals US, INC. | $359.60 | 2024-2025 | Uptravi, Opsumit |
| Abbott Laboratories | $302.58 | 2019-2025 | Freestyle Libre 2, Freestyle Libre 3 |
| Sanofi-Aventis U.S. LLC | $292.19 | 2019-2022 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $244.59 | 2019-2023 | |
| Corcept Therapeutics | $231.92 | 2023-2024 | Korlym |
| Janssen Pharmaceuticals, INC | $228.07 | 2019-2021 | |
| Otsuka America Pharmaceutical, INC. | $207.17 | 2024-2025 | Jynarque |
| Dexcom, INC. | $167.69 | 2023 | Dexcom G7 Gss (161), Dexcom G6 Transmitter |
| Astellas Pharma US INC | $156.03 | 2025 | Veozah |
| Aroa Biosurgery Incorporated | $154.29 | 2024 | |
| Mimedx Group, INC. | $146.52 | 2024 | |
| Ardelyx, INC. | $140.38 | 2024-2025 | Ibsrela |
| Axsome Therapeutics, INC. | $132.01 | 2024 | Auvelity |
| Therapeuticsmd, INC. | $130.80 | 2019-2020 | |
| Biohaven Pharmaceuticals, INC. | $125.01 | 2021 | |
| Genzyme Corporation | $120.24 | 2024 | |
| Exact Sciences Corporation | $116.18 | 2023-2025 | Cologuard Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $112.14 | 2021-2024 | Trintellix |
| Merck Sharp & Dohme LLC | $89.56 | 2019-2024 | Gardasil 9, Rotateq, Vaxneuvance |
| Ironwood Pharmaceuticals, INC | $88.84 | 2019 | |
| Sumitomo Pharma America, INC. | $83.81 | 2023-2025 | Gemtesa |
| Gilead Sciences, INC. | $62.74 | 2019 | |
| Sientra, INC. | $31.77 | 2020 | |
| Eisai INC. | $25.97 | 2025 | |
| Inspire Medical Systems, INC. | $25.61 | 2024 | Inspire |
| Genentech USA, INC. | $21.69 | 2019 | |
| Biocryst US Sales Co., LLC | $19.91 | 2025 | Orladeyo |
| Zimmer Biomet Holdings, INC. | $17.51 | 2025 | Rosa |
| Amneal Pharmaceuticals LLC | $15.77 | 2025 | Unithroid |
| Amag Pharmaceuticals, INC. | $12.56 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arabinda Chatterjee listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.